TG-101348: Tyrosine-protein kinase JAK2 inhibitor receptor-type tyrosine-protein kinase FLT3 inhibitor treatment of myeloproliferative diseases

Drugs of the Future

Volumn 36, Issue 11, 2011, Pages 819-824

  Harry, Brian L ^a   Eckhardt, S Gail ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; CYTOKINE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO]PYRIMIDIN 4 YLAMINO]BENZENESULFONAMIDE; SAR 302503; TG 101348; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHUMAN; PATHOGENESIS; POLYCYTHEMIA VERA; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; VOMITING;

EID: 84952987666     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.11.1633943     Document Type: Article

References (45)

1. Cao, J.J., Hood, J., Lohse, D. et al. (TargaGen, Inc.). Bi-aryl meta-pyrimidine inhibitors of kinases. EP 1951684, JP 2009513703, US 2007191405, WO 2007053452.
2. Noronha, G., Mak, C.C., Cao, J. et al. (TargaGen, Inc.). Bi-aryl meta-pyrimidine inhibitors of kinases. US 2007259904, US 7825246.
3. Mesa, R.A., Silverstein, M.N., Jacobsen, S.J., Wollan, P.C., Tefferi, A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976-1995. Am J Hematol 1999, 61(1): 10-5. (Pubitemid 29218171)
4. Abdel-Wahab, O.I., Levine, R.L. Primary myelofibrosis: Update on definition, pathogenesis, and treatment. Annu Rev Med 2009, 60: 233-45.
5. Passamonti, F., Cervantes, F., Vannucchi, A.M. et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWGMRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115(9): 1703-8.
6. Kerbauy, D.M., Gooley, T.A., Sale, G.E. et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007, 13(3): 355-65.
7. Baxter, E.J., Scott, L.M., Campbell, P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464): 1054-61. (Pubitemid 40386783)
8. James, C., Ugo, V., Le Couedic, J.P. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037): 1144-8. (Pubitemid 40663494)
9. Kralovics, R., Passamonti, F., Buser, A.S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17): 1779-90. (Pubitemid 40570926)
10. Levine, R.L., Wadleigh, M., Cools, J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4): 387-97. (Pubitemid 40544655)
11. Jones, A.V., Chase, A., Silver, R.T. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009, 41(4): 446-9.
12. Kilpivaara, O., Mukherjee, S., Schram, A.M. et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009, 41(4): 455-9.
13. Olcaydu, D., Harutyunyan, A., Jager, R. et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 41(4): 450-4.
14. Quintas-Cardama, A., Kantarjian, H., Cortes, J., Verstovsek, S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011, 10(2): 127-40.
15. Ihle, J.N. The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Semin Immunol 1995, 7(4): 247-54.
16. Tiedt, R., Hao-Shen, H., Sobas, M.A., Looser, R., Dirnhofer, S., Schwaller, J., Skoda, R.C. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111(8): 3931-40.
17. Scott, L.M., Tong, W., Levine, R.L. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356(5): 459-68. (Pubitemid 46193073)
18. Pietra, D., Li, S., Brisci, A. et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111(3): 1686-9. (Pubitemid 351213460)
19. Pardanani, A., Lasho, T.L., Finke, C., Hanson, C.A., Tefferi, A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007, 21(9): 1960-3. (Pubitemid 47299970)
20. Wernig, G., Kharas, M.G., Okabe, R. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13(4): 311-20. (Pubitemid 351446195)
21. Geron, I., Abrahamsson, A.E., Barroga, C.F. et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008, 13(4): 321-30. (Pubitemid 351446196)
22. Wernig, G., Mercher, T., Okabe, R., Levine, R.L., Lee, B.H., Gilliland, D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107(11): 4274-81. (Pubitemid 43801351)
23. Mullally, A., Lane, S.W., Ball, B. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17(6): 584-96.
24. Prchal, J.F., Axelrad, A.A. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 1974, 290(24): 1382.
25. Lasho, T.L., Tefferi, A., Hood, J.D., Verstovsek, S., Gilliland, D.G., Pardanani, A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008, 22(9): 1790-2.
26. Pardanani, A., Gotlib, J.R., Jamieson, C. et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011, 29(7): 789-96.
27. Cervantes, F., Dupriez, B., Pereira, A. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113(13): 2895-901.
28. Scott, L.M., Campbell, P.J., Baxter, E.J. et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005, 106(8): 2920-1. (Pubitemid 41510774)
29. Lee, J.W., Soung, Y.H., Kim, S.Y. et al. Absence of JAK2 V617F mutation in gastric cancers. Acta Oncol 2006, 45(2): 222-3.
30. Motte, N., Saulnier, P., Le Couedic, J.P. et al. Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors. Int J Cancer 2007, 121(9): 2113-5. (Pubitemid 47463178)
31. Jeong, E.G., Kim, M.S., Nam, H.K. et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008, 14(12): 3716-21.
32. Italiano, A., Attias, R., Aurias, A. et al. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet Cytogenet 2006, 167(2): 122-30. (Pubitemid 43776948)
33. Gao, B., Shen, X., Kunos, G., Meng, Q., Goldberg, I.D., Rosen, E.M., Fan, S. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001, 488(3): 179-84. (Pubitemid 32103593)
34. Yu, H., Jove, R. The STATs of cancer - New molecular targets come of age. Nat Rev Cancer 2004, 4(2): 97-105. (Pubitemid 38198738)
35. Levy, D.E., Inghirami, G. STAT3: A multifaceted oncogene. Proc Natl Acad Sci U S A 2006, 103(27): 10151-2. (Pubitemid 44051135)
36. Masuda, M., Wakasaki, T., Suzui, M., Toh, S., Joe, A.K., Weinstein, I.B. Stat3 orchestrates tumor development and progression: The Achilles' heel of head and neck cancers? Curr Cancer Drug Targets 2010, 10(1): 117-26.
37. Grandis, J.R., Drenning, S.D., Zeng, Q. et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000, 97(8): 4227-32. (Pubitemid 30226115)
38. Niu, G., Wright, K.L., Huang, M. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13): 2000-8. (Pubitemid 34270888)
39. Bowman, T., Broome, M.A., Sinibaldi, D. et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 2001, 98(13): 7319-24. (Pubitemid 32567946)
40. Silvennoinen, O., Schindler, C., Schlessinger, J., Levy, D.E. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science 1993, 261(5129): 1736-9. (Pubitemid 23332923)
41. Zhong, Z., Wen, Z., Darnell, J.E. Jr. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264(5155): 95-8. (Pubitemid 24144493)
42. Ruff-Jamison, S., Zhong, Z., Wen, Z., Chen, K., Darnell, J.E., Jr., Cohen, S. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J Biol Chem 1994, 269(35): 21933-5. (Pubitemid 24282108)
43. Hedvat, M., Huszar, D., Herrmann, A. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16(6): 487-97.
44. Berishaj, M., Gao, S.P., Ahmed, S. et al. Stat3 is tyrosine- phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007, 9(3): R32.
45. Gao, S.P., Mark, K.G., Leslie, K. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117(12): 3846-56. (Pubitemid 350224094)